Heidi A. Lane

Heidi A. Lane

Auto-generated profile, based on publicly available information

Heidi A. Lane

Basilea Pharmaceutica International Ltd., Basel, Switzerland

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2016 in Science Advances
Verified
Journal Article
Open access
PDF file
DBDon Benjamin
Don Benjamin
MCMarco Colombi
Marco Colombi
SHSravanth K. Hindupur
Sravanth K. Hindupur
CBCharles Betz
Charles Betz
HLHeidi A. Lane
Heidi A. Lane
MHMichael Hall
Michael Hall
Synthetic lethality between the clinically approved noncancer drugs metformin and syrosingopine specifically kills cancer cells.

1 November 2016 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
RBRaphaël Bergès
Raphaël Bergès
Aurélie Tchoghandjian-AuphanAurélie Tchoghandjian-Auphan
Aurélie Tchoghandjian-Auphan
SHStéphane Honoré
Stéphane Honoré
MEMarie-Anne Estève
Marie-Anne Estève
DFDominique Figarella-Branger
Dominique Figarella-Branger
DBDiane Braguer
Diane Braguer
Glioblastoma patients have limited treatment options. Cancer stem-like cells (CSLC) contribute to glioblastoma invasiveness and repopulation; hence, they represent promising targets for novel therapies. BAL101553 is a prodrug of BAL27862, a novel microtubule-destabilizing agent inhibiting tumor cell proliferation through activation of the spindle assembly checkpoint, which is currently in phase I/II clinical development. Broad anticancer activity has been demonstrated against human cancer models, including tumors refractory to conventional treatments. We have shown that overexpression of microtubule + end-binding 1-protein (EB1) correlates with glioblastoma progression and poor survival. Here, we show that BAL27862 inhibits the growth of two glioblastoma CSLCs. As EB1 is overexpressed in the CSLC line GBM6, which displays a high tumorigenicity and infiltrative pattern of migration in vivo, we investigated drug activity on GBM6 according to EB1 expression. BAL27862 inhibited migration and colony formation at subcytotoxic concentrations in EB1-expressing control cells (GBM6-sh0) but only at cytotoxic concentrations in EB1-downregulated (GBM-shE1) cells. Three administrations of BAL101553 were sufficient to provoke an EB1-dependent survival benefit in tumor-bearing mice. Patterns of invasion and quantification of tumor cells in brain demonstrated that GBM6-sh0 cells were more invasive than GBM6-shEB1 cells, and that the antiproliferative and anti-invasive effects of BAL101553 were more potent in mice bearing control tumors than in EB1-downregulated tumors. This was associated with inhibition of stem cell properties in the GBM6-sh0 model. Finally, BAL27862 triggered astrocytic differentiation of GBM6 in an EB1-dependent manner. These results support the potential of BAL101553 for glioblastoma treatment, with EB1 expression as a predictive biomarker of response. Mol Cancer Ther; 15(11); 2740–9. ©2016 AACR.

1 July 2005 in Nature Reviews Cancer
Verified
Journal Article
Open access
PDF file
NHNancy Hynes
Nancy Hynes
HLHeidi A. Lane
Heidi A. Lane
Nature Rev. Cancer 5, 341–354 (2005) The authors would like to correct Figure 4b of this article. The statement in the figure legend that reads “The epidermal growth factor receptor variant III (EGFRvarIII) cannot bind cetuximab or matuzumab” is incorrect. Wu and colleagues1 have shown that cetuximab does bind EGFRvarIII.

20 May 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
EDEmma Dean
Emma Dean
UBUdai Banerji
Udai Banerji
RGRomina Girotti
Romina Girotti
INIon Niculescu-Duvaz
Ion Niculescu-Duvaz
FLFilipa Lopes
Filipa Lopes
CSCaroline Springer
Caroline Springer
TPS9597 Background: Over 70,000 patients are diagnosed with malignant melanoma in the USA every year with a high proportion occurring in young people. Although treatments targeting the mitogen activated protein kinase signal transduction pathway including BRAF inhibitors have improved survival for patients with BRAF mutated melanoma, their utility is limited by intrinsic and acquired resistance of diverse mechanisms. Patients with a RAS mutated melanoma also represent a current unmet need. CCT3833 is a potent inhibitor of mutant BRAF, CRAF and SRC kinases. Preclinical data using CCT3833 in a range of mutant RAF or RAS cell lines in vitro and human tumour xenograft models in vivo demonstrated activity, including melanoma patient-derived xenografts with intrinsic or acquired resistance to selective BRAF inhibitors. These data support clinical development of CCT3833 in humans. Methods: This ongoing open-label, multi-centre Phase I trial of CCT3833 is in two parts; an initial dose escalation stage (Part A) in a rolling six design, followed by a dose expansion (Part B). The primary objectives are to evaluate the safety and tolerability profile of CCT3833 and establish the Recommended Phase 2 Dose (RP2D). CCT3833 is administered orally once daily on a continuous basis over a 28-day cycle. In Part A, a single dose is administered for safety and pharmacokinetic (PK) purposes prior to commencing continuous dosing. Secondary objectives include characterisation of the PK profile and correlation with tolerability / efficacy of CCT3833 in humans and assessment of response (radiological or clinical), supported by PD analyses. Eligible subjects include patients with advanced solid malignancies with performance status 0 to 1, fit for entry into a Phase 1 clinical trial. Part B will enrol patients with BRAF- or RAS- mutated metastatic melanoma into 3 cohorts i) treatment naïve V600E BRAF mutant melanoma ii) V600E BRAF mutant melanoma with progression on BRAF inhibitor therapy or iii) RAS mutant melanoma. Three cohorts of the dose escalation have been completed without DLT. Enrolment to cohort 4 began in January 2016. Clinical trial information: NCT02437227. Clinical trial information: NCT02437227.

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
EZElisa Zanini
Elisa Zanini
NFNicole Forster-Gross
Nicole Forster-Gross
FBFelix Bachmann
Felix Bachmann
NWNicole Willemsen-Seegers
Nicole Willemsen-Seegers
JMJos de Man
Jos de Man
HLHeidi A. Lane
Heidi A. Lane
Background: BAL0891 is a dual inhibitor of threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1). These kinases collaborate in activating the mitotic spindle assembly checkpoint (SAC) at the kinetochore (KT) to regulate chromosome alignment and segregation prior to mitotic exit. In this work, kinase inhibition by BAL0891 was linked to effects on SAC integrity and aberrant mitotic progression in tumor cells. Comparison with a TTK-specific inhibitor (CFI-402257, CFI) allowed further evaluation of the contribution of dual TTK/PLK1 inhibition to anti-cancer activity, associated with a promising anti-proliferative profile across diverse tumor cell lines. Methods: Kinase assays used a radiometric assay. Target residency was measured using surface plasmon resonance with recombinant kinase. Anti-proliferative activity was assessed with crystal violet or YO-PRO assay (5 days incubation), in-cell target inhibition by immunoblotting for phospho-TTK following drug wash-out. Effects on SAC integrity were followed by immunoprecipitation (IP) mitotic progression by flow cytometry/mitotic marker expression. Cells were blocked in mitosis using the microtubule-targeting agent nocodazole or the PLK1 inhibitor onvansertib. SAC KT accumulation was evaluated by immunofluorescence (IF) for co-localization of BubR1 with CENPC. Comparative studies with CFI used anti-proliferative IC50 concentrations. Results: In vitro kinase profiling showed that BAL0891 has low nM IC50s against TTK and PLK1, with prolonged TTK (>12 h) and transient PLK1 (4 min) target residency. Prolonged TTK inhibition (≥38 h) was also observed in HT29 tumor cells. Consistent with a dominant TTK-targeting activity, BAL0891 treatment of HT29 cells blocked in mitosis with nocodazole or the PLK1 inhibitor onvansertib led to aberrant mitotic release and accumulation of polyploid cells. This was preceded by SAC disruption as visualized by IP assays. Effects on the SAC and mitotic exit were evaluated in comparative studies with CFI; BAL0891 exhibited faster kinetics for both parameters suggesting a contribution of PLK1 inhibition. This was confirmed by directly evaluating acute effects on SAC integrity at the KT by IF. Specifically, 1 h BAL0891 treatment of mitotic HT29 cells resulted in a highly reproducible and significant reduction in KT-associated SAC (p5 uM). Conclusion: BAL0891 is a novel dual TTK/PLK1 mitotic checkpoint inhibitor. In tumor cells, prolonged effects on TTK and transient effects on PLK1 contribute to rapid SAC disruption and aberrant mitotic exit. This is associated with potent anti-proliferative activity in diverse tumor lines. Citation Format: Elisa Zanini, Nicole Forster-Gross, Felix Bachmann, Nicole Willemsen-Seegers, Jos de Man, Guido J. Zaman, Rogier C. Buijsman, Anna Groner, Mila Roceri, Karin Burger, Paul McSheehy, Laurenz Kellenberger, Heidi A. Lane. BAL0891: A novel, small molecule, dual TTK/PLK1 mitotic checkpoint inhibitor (MCI) that drives aberrant tumor cell division [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5646.

18 February 2026 in MedEdPORTAL
Verified
Journal Article
Open access
JNJaclyn Nunziato
Jaclyn Nunziato
CLChloe Lessard
Chloe Lessard
NKNatalie Karp
Natalie Karp
HLHeidi Lane
Heidi Lane
TLTonja Locklear
Tonja Locklear
KSKimberly Simcox
Kimberly Simcox
Trauma affects 90% of individuals and has profound impacts on health, making it essential for medical trainees to recognize its effects. Trauma-informed care (TIC) offers a framework for developing these skills. Despite its importance, no TIC curriculum integrates community feedback into its design. To address this gap, we developed a 4-hour TIC curriculum that incorporates community insight, clinical expertise, and practical communication training. The curriculum design followed community-based participatory research principles, engaging community members as contributors. The training included a dynamic combination of didactic lectures, video demonstrations, small-group role-play, and an OSCE, supported by a novel TIC toolkit. Community partners were trained as standardized patients (SPs). We assessed student outcomes through pre- and postsession surveys, employing 5-point Likert scales and open-ended responses. Additionally, a custom assessment tool was developed to evaluate OSCE performance, with SPs providing structured feedback. Thirty-four third-year medical students participated, with 100% survey completion. Quantitative analysis revealed significant increases in students’ understanding of TIC principles and confidence in applying them from pre- to postsession (p < .05 for all metrics). Students demonstrated strong performance on the OSCE, achieving a mean OSCE performance score of 31.4/38 (or overall score of 82.6%). SP feedback highlighted the students’ ability to engage empathetically and effectively in trauma-sensitive encounters. This novel TIC curriculum on women's health demonstrates a successful, scalable model for integrating TIC training into medical education. By embedding community voices and combining evidence-based principles with experiential learning, this program addresses educational gaps in TIC medical education.